100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
TEST BANK LEHNE'S PHARMACOLOGY FOR NURSING CARE, 11TH EDITION $14.00
Add to cart

Exam (elaborations)

TEST BANK LEHNE'S PHARMACOLOGY FOR NURSING CARE, 11TH EDITION

 0 purchase
  • Course
  • LEHNE\\\'S PHARMACOLOGY FOR NURSING CARE
  • Institution
  • LEHNE\\\'S PHARMACOLOGY FOR NURSING CARE

TEST BANK LEHNE'S PHARMACOLOGY FOR NURSING CARE, 11TH EDITION TEST BANK LEHNE'S PHARMACOLOGY FOR NURSING CARE, 11TH EDITION

Preview 4 out of 751  pages

  • March 11, 2025
  • 751
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers
book image

Book Title:

Author(s):

  • Edition:
  • ISBN:
  • Edition:
  • LEHNE'S PHARMACOLOGY FOR NURSING CARE
  • LEHNE'S PHARMACOLOGY FOR NURSING CARE
avatar-seller
NURSEMARYSEACOLE
FULL TEST BANK

LEHNE'S PHARMACOLOGY FOR NURSING CARE,
11TH EDITION

BY BURCHUM, ROSENTHAL; || ALL CHAPTERS 1-112

,TEST BANK - LEHNE'S PHARMACOLOGY FOR
NURSING CARE, 12TH EDITION ( JACQUELINE
BURCHUM, LAURA ROSENTHAL; 2024) LATEST
EDITION || ALL CHAPTERS 1-112

,TABLE OF CONTENTS
CHAPTER 01: ORIENTATION TO PHARMACOLOGY ........................................................................................ 6
CHAPTER 02: APPLICATION OF PHARMACOLOGY IN NURSING PRACTICE .................................................... 8
CHAPTER 03: DRUG REGULATION, DEVELOPMENT, NAMES, AND INFORMATION ..................................... 15

CHAPTER 04: PHARMACOKINETICS ............................................................................................................. 18
CHAPTER 05: PHARMACODYNAMICS .......................................................................................................... 25
CHAPTER 06: DRUG INTERACTIONS ............................................................................................................ 30
CHAPTER 07: ADVERSE DRUG REACTIONS AND MEDICATION ERRORS ...................................................... 36

CHAPTER 08: INDIVIDUAL VARIATION TO DRUG RESPONSES ..................................................................... 43

CHAPTER 09: GENETIC AND GENOMIC CONSIDERATIONS .......................................................................... 49
CHAPTER 10: INTRODUCTION TO IMMUNOMODULATORS ........................................................................ 54

CHAPTER 11: DRUG THERAPY DURING PREGNANCY AND BREAST-FEEDING .............................................. 58
CHAPTER 12: DRUG THERAPY IN PEDIATRIC PATIENTS ............................................................................... 63

CHAPTER 13: DRUG THERAPY IN OLDER ADULTS ........................................................................................ 69
CHAPTER 14: BASIC PRINCIPLES OF NEUROPHARMACOLOGY .................................................................... 76
CHAPTER 15: PHYSIOLOGY OF THE PERIPHERAL NERVOUS SYSTEM........................................................... 79

CHAPTER 16: MUSCARINIC AGONISTS ........................................................................................................ 84
CHAPTER 17: MUSCARINIC ANTAGONISTS .................................................................................................. 88
CHAPTER 18: CHOLINESTERASE INHIBITORS AND THEIR USE IN MYASTHENIA GRAVIS ............................. 92
CHAPTER 19: DRUGS THAT BLOCK NICOTINIC CHOLINERGIC TRANSMISSION ............................................ 97
CHAPTER 20: ADRENERGIC AGONISTS ...................................................................................................... 103
CHAPTER 21: ADRENERGIC ANTAGONISTS................................................................................................ 108
CHAPTER 22: INDIRECT-ACTING ANTIADRENERGIC AGENTS .................................................................... 116
CHAPTER 23: INTRODUCTION TO CENTRAL NERVOUS SYSTEM PHARMACOLOGY ................................... 122
CHAPTER 24: DRUGS FOR PARKINSON DISEASE ........................................................................................ 126

CHAPTER 25: DRUGS FOR ALZHEIMER DISEASE ........................................................................................ 134

CHAPTER 26: DRUGS FOR MULTIPLE SCLEROSIS ....................................................................................... 139
CHAPTER 27: DRUGS FOR SEIZURE DISORDERS ........................................................................................ 146
CHAPTER 28: DRUGS FOR MUSCLE SPASM AND SPASTICITY .................................................................... 156

, CHAPTER 29: LOCAL ANESTHETICS ............................................................................................................ 161

CHAPTER 30: GENERAL ANESTHETICS ....................................................................................................... 167
CHAPTER 31: OPIOID ANALGESICS, OPIOID ANTAGONISTS, AND NONOPIOID CENTRALLY ACTING ANALGESICS
.................................................................................................................................................................. 174
CHAPTER 32: PAIN MANAGEMENT IN PATIENTS WITH CANCER ............................................................... 182

CHAPTER 33: DRUGS FOR HEADACHE ....................................................................................................... 191
CHAPTER 34: ANTIPSYCHOTIC AGENTS AND THEIR USE IN SCHIZOPHRENIA ............................................ 198

CHAPTER 35: ANTIDEPRESSANTS .............................................................................................................. 205
CHAPTER 36: DRUGS FOR BIPOLAR DISORDER.......................................................................................... 215

CHAPTER 37: SEDATIVE-HYPNOTIC DRUGS ............................................................................................... 221
CHAPTER 38: MANAGEMENT OF ANXIETY DISORDERS ............................................................................. 229
CHAPTER 40: SUBSTANCE USE DISORDERS I: BASIC CONSIDERATIONS .................................................... 240
CHAPTER 41: SUBSTANCE USE DISORDERS II: ALCOHOL ........................................................................... 245
CHAPTER 42: SUBSTANCE USE DISORDERS III: NICOTINE.......................................................................... 254

CHAPTER 43: SUBSTANCE USE DISORDERS IV: MAJOR DRUGS OF ABUSE OTHER THAN ALCOHOL AND NICOTINE
.................................................................................................................................................................. 259
CHAPTER 44: DIURETICS ............................................................................................................................ 268

CHAPTER 45: AGENTS AFFECTING THE VOLUME AND ION CONTENT OF BODY FLUIDS ........................... 274
CHAPTER 46: REVIEW OF HEMODYNAMICS .............................................................................................. 281
CHAPTER 47: DRUGS ACTING ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ............................. 284
CHAPTER 48: CALCIUM CHANNEL BLOCKERS ............................................................................................ 290
CHAPTER 49: VASODILATORS .................................................................................................................... 294

CHAPTER 50: DRUGS FOR HYPERTENSION ................................................................................................ 299
CHAPTER 51: DRUGS FOR HEART FAILURE ................................................................................................ 309

CHAPTER 52: ANTIDYSRHYTHMIC DRUGS ................................................................................................. 319
CHAPTER 53: DRUGS THAT HELP NORMALIZE CHOLESTEROL AND TRIGLYCERIDE LEVELS ....................... 329
CHAPTER 54: DRUGS FOR ANGINA PECTORIS ........................................................................................... 339
CHAPTER 55: ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC DRUGS ....................................... 347
CHAPTER 56: MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION ........................................... 356

CHAPTER 57: DRUGS FOR HEMOPHILIA .................................................................................................... 363

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller NURSEMARYSEACOLE. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $14.00. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

71250 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 15 years now

Start selling
$14.00
  • (0)
Add to cart
Added